Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;2010(41):178-80.
doi: 10.1093/jncimonographs/lgq025.

Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective

Nina Bijker  1 , Geertjan van Tienhoven
Affiliations
Review

Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective

Nina Bijker et al. J Natl Cancer Inst Monogr. 2010.

Abstract

Four randomized clinical trials have shown unanimously the benefit of 50 Gy whole-breast radiotherapy in breast-conserving therapy (BCT) for ductal carcinoma in situ (DCIS). The risk of both DCIS and invasive local recurrence is reduced with about 50%, and this effect is similar for all clinical and histological subgroups analyzed. Younger age and involved margin status are the most important factors for an increased risk of local recurrence. In these subgroups, even with radiotherapy, the observed local recurrence rates are more than 20% at 10 years, which is considerably higher than reported local recurrence rates after BCT for invasive breast cancer. The optimal radiotherapy dose in BCT for DCIS has yet to be established. Also, at present, a subgroup of lesions in which the recurrence rate is so low that radiotherapy can be safely omitted has not yet been identified.

PubMed Disclaimer

Figures

Figure 1
Figure 1
EORTC 10853; local recurrence by age. O = observed (number of events); N = number (number of patients).
Figure 2
Figure 2
EORTC 10853; local recurrence by margin status. *In trial, margins had to be free; in this subgroup, margins were not reported (free) in pathology report. O = observed (number of events); N = number (number of patients).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400–418. - PubMed
    1. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–3387. - PubMed
    1. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102. - PubMed
    1. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–1252. - PubMed
    1. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2009;21(1) CD000563. - PubMed

MeSH terms